HRP20131170T1 - Nova antibakterijska sredstva za lijeäśenje gram-pozitivnih infekcija - Google Patents

Nova antibakterijska sredstva za lijeäśenje gram-pozitivnih infekcija Download PDF

Info

Publication number
HRP20131170T1
HRP20131170T1 HRP20131170AT HRP20131170T HRP20131170T1 HR P20131170 T1 HRP20131170 T1 HR P20131170T1 HR P20131170A T HRP20131170A T HR P20131170AT HR P20131170 T HRP20131170 T HR P20131170T HR P20131170 T1 HRP20131170 T1 HR P20131170T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
intended
bacteria
resistant
accordance
Prior art date
Application number
HRP20131170AT
Other languages
English (en)
Croatian (hr)
Inventor
Andre Lee Pearson
Chester A. Metcalf Iii
Jing Li
Original Assignee
Cubist Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cubist Pharmaceuticals, Inc. filed Critical Cubist Pharmaceuticals, Inc.
Publication of HRP20131170T1 publication Critical patent/HRP20131170T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20131170AT 2008-12-22 2009-12-18 Nova antibakterijska sredstva za lijeäśenje gram-pozitivnih infekcija HRP20131170T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13987508P 2008-12-22 2008-12-22
PCT/US2009/068747 WO2010075215A1 (en) 2008-12-22 2009-12-18 Novel antibacterial agents for the treatment of gram positive infections

Publications (1)

Publication Number Publication Date
HRP20131170T1 true HRP20131170T1 (hr) 2014-01-03

Family

ID=41718893

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20131170AT HRP20131170T1 (hr) 2008-12-22 2009-12-18 Nova antibakterijska sredstva za lijeäśenje gram-pozitivnih infekcija

Country Status (26)

Country Link
US (3) US8507647B2 (enExample)
EP (2) EP2674437A1 (enExample)
JP (1) JP5670914B2 (enExample)
KR (1) KR101717795B1 (enExample)
CN (1) CN102325787B (enExample)
AR (1) AR074833A1 (enExample)
AU (1) AU2009330245C1 (enExample)
BR (1) BRPI0923567A2 (enExample)
CA (1) CA2747965C (enExample)
CY (1) CY1114883T1 (enExample)
DK (1) DK2379580T3 (enExample)
ES (1) ES2442167T3 (enExample)
HR (1) HRP20131170T1 (enExample)
IL (1) IL213638A0 (enExample)
MX (1) MX2011006803A (enExample)
NZ (1) NZ594019A (enExample)
PL (1) PL2379580T3 (enExample)
PT (1) PT2379580E (enExample)
RS (1) RS53152B (enExample)
RU (1) RU2512396C2 (enExample)
SG (1) SG172299A1 (enExample)
SI (1) SI2379580T1 (enExample)
SM (1) SMT201400037B (enExample)
TW (1) TWI444198B (enExample)
WO (1) WO2010075215A1 (enExample)
ZA (1) ZA201104693B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162567A1 (en) * 2011-05-26 2012-11-29 Cubist Pharmaceuticals, Inc. Cb-183,315 compositions and related methods
US10377699B2 (en) * 2013-11-06 2019-08-13 The University Of Hong Kong Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue
WO2015172047A1 (en) * 2014-05-08 2015-11-12 Merck Sharp & Dohme Corp. Cyclic peptide compounds and related methods, salts and compositions
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
SMT202000249T1 (it) * 2016-04-22 2020-07-08 Astrazeneca Ab Inibitori di mcl1 macrociclici per il trattamento di cancro
US10098890B2 (en) 2016-10-29 2018-10-16 Cipla Limited Stable carfilzomib formulations
IT201600127655A1 (it) * 2016-12-16 2018-06-16 Gnosis Spa Processo per la purificazione di antibiotici lipopolipeptidici
US10072045B1 (en) 2017-06-26 2018-09-11 Ramapo Pharmaceuticals, Inc. Antibacterial lipopeptides and methods for their preparation and use
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
RU2762182C1 (ru) * 2020-12-08 2021-12-16 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе" Гауземицины А и В - гликолипопептидные антибактериальные антибиотики и способ их получения

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
CA1195983A (en) 1982-02-27 1985-10-29 Graham Walker Antibacterial 1-normon-2-yl thiazoles and - oxazoles
US4399067A (en) 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4396543A (en) 1982-05-21 1983-08-02 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
IL68700A0 (en) * 1982-05-21 1983-09-30 Lilly Co Eli Improvements relating to a-21978c cyclic peptide derivatives and their production
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
DD238068A5 (de) 1984-10-09 1986-08-06 ���@�����@�K@�������k�� Verfahren zur herstellung von derivaten der cyclopeptidantibiotika a-21978 c
CA1315229C (en) 1987-06-10 1993-03-30 Eli Lilly And Company Chromatographic purification process
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
EP0460882B1 (en) 1990-06-07 1996-07-24 Eli Lilly And Company Lipopeptide deacylase
JPH09504512A (ja) 1993-08-13 1997-05-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 抗菌活性、抗マイコプラズマ活性、抗真菌類活性および除草活性を有するモン酸ａおよびｃの誘導体
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
EP1854877B1 (en) 1996-03-08 2012-02-08 Astellas Pharma Inc. Process for the deacylation of cyclic lipopeptides
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
DK1115417T3 (da) 1998-09-25 2006-07-31 Cubist Pharm Inc Anvendelse af daptomycin
CN1181367C (zh) 1999-11-03 2004-12-22 惠特克公司 多光纤阵列的光电模块
IL150223A0 (en) 1999-12-15 2002-12-01 Cubist Pharm Inc Lipopeptides and pharmaceutical compositions containing the same
CN1423656A (zh) 1999-12-15 2003-06-11 卡比斯特制药公司 作为抗菌剂的脂肽
CA2394313A1 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Novel lipopeptides as antibacterial agents
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
EP1423137B1 (en) 2001-08-06 2009-04-29 Cubist Pharmaceuticals, Inc. Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
JP2008519848A (ja) * 2004-11-12 2008-06-12 キュービスト ファーマシューティカルズ， インコーポレイテッド 抗感染性リポペプチド

Also Published As

Publication number Publication date
CA2747965A1 (en) 2010-07-01
TWI444198B (zh) 2014-07-11
KR20110114592A (ko) 2011-10-19
NZ594019A (en) 2013-08-30
AR074833A1 (es) 2011-02-16
SI2379580T1 (sl) 2014-02-28
EP2379580B1 (en) 2013-10-23
PT2379580E (pt) 2014-01-20
US20150337013A1 (en) 2015-11-26
ES2442167T3 (es) 2014-02-10
PL2379580T3 (pl) 2014-05-30
CY1114883T1 (el) 2016-12-14
WO2010075215A1 (en) 2010-07-01
RS53152B (sr) 2014-06-30
IL213638A0 (en) 2011-07-31
JP5670914B2 (ja) 2015-02-18
CN102325787B (zh) 2014-05-28
HK1161886A1 (en) 2012-08-10
AU2009330245A1 (en) 2011-08-04
TW201028161A (en) 2010-08-01
US8507647B2 (en) 2013-08-13
MX2011006803A (es) 2011-09-06
US20140073558A1 (en) 2014-03-13
RU2512396C2 (ru) 2014-04-10
RU2011130278A (ru) 2013-01-27
EP2674437A1 (en) 2013-12-18
JP2012513467A (ja) 2012-06-14
AU2009330245C1 (en) 2013-09-26
CN102325787A (zh) 2012-01-18
AU2009330245B2 (en) 2013-05-02
ZA201104693B (en) 2013-01-30
CA2747965C (en) 2017-06-27
SG172299A1 (en) 2011-07-28
US20100184649A1 (en) 2010-07-22
BRPI0923567A2 (pt) 2016-09-27
KR101717795B1 (ko) 2017-03-17
EP2379580A1 (en) 2011-10-26
DK2379580T3 (da) 2014-01-20
SMT201400037B (it) 2014-05-07

Similar Documents

Publication Publication Date Title
RU2011130278A (ru) Новые противобактериальные средства для лечения грамположительных инфекций
JP2012513467A5 (enExample)
El-Feky et al. Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces
ES2565564T3 (es) Una composición que comprende un antibiótico y un dispersante
JP2022058682A5 (enExample)
del Prado et al. Biofilm formation by Streptococcus pneumoniae strains and effects of human serum albumin, ibuprofen, N-acetyl-l-cysteine, amoxicillin, erythromycin, and levofloxacin
RU2018107249A (ru) Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики
HRP20160038T1 (hr) Bakteriofag ili litiäśki protein izveden iz bakteriofaga koji je uäśinkovit za tretiranje biofilma staphylococcus aureusa
RU2014149351A (ru) Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий
EA201101319A1 (ru) Композиции и способы элиминации грамотрицательных бактерий
CN101175531A (zh) 包含一种抗菌药以及一种选自香芹醇、麝香草酚、丁香酚、冰片、香芹酚的活性物质的药物组合物
Fan et al. Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria
Zhou et al. Potential of berberine to enhance antimicrobial activity of commonly used antibiotics for dairy cow mastitis caused by multiple drug-resistant Staphylococcus epidermidis infection
MX2007007235A (es) Combinacion de antibioticos para proporcionar una solucion total al tratamiento de infecciones.
RU2015134149A (ru) Композиции и способы лечения бактериальных инфекций
RU2004118716A (ru) Лечение инфекции, вызываемой микроорганизмами
WO2005070945A8 (ja) メチシリン耐性黄色ブドウ球菌（ｍｒｓａ）に有効な新規アミノグリコシド系抗生物質
JP2017533177A5 (enExample)
JP2008520660A5 (enExample)
TW200510541A (en) Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
JP2018521143A5 (enExample)
JP2018504434A (ja) オーラノフィンを使用してバイオフィルムを抑制及び分散する方法
CN108420814A (zh) 一种nps-2143用于抗菌的新用途
EA200701384A1 (ru) Антибиотик 107891, его факторы a1 и a2, фармацевтически приемлемые соли и композиции и их применение
WO2009124086A3 (en) Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections